About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
S
Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis but is Actionable
By
University of Miami Sylvester Comprehensive Cancer Center
FEATURING
Sangeetha Venugopal
By
University of Miami Sylvester Comprehensive Cancer Center
FEATURING
Sangeetha Venugopal
172 views
March 18, 2024
1 Comment
Login to view comments.
Click here to Login
Featured Video
11:12
Stemline
A proven CD123 targeted therapy for BPDCN
Feat.
H. Erba
Featured Video
37:21
Amgen Sponsorship
New Approval for Frontline Consolidation in Patients with CD19-posit…
Feat.
J. Mccloskey
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
11:12
Stemline
A proven CD123 targeted therapy for BPDCN
Feat.
H. Erba
22:37
Insights from 2023 ASH Annual Meeting
AML and MDS Highlights & Key Takeaways
Feat.
T. Badar
27:49
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
Feat.
T. Badar
17:51
Indy Hematology Review
Treatment of AML: Managing the Patient When Transplant Is Not an Opt…
Feat.
H. Erba
19:21
SOHO Brazil 2024
Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde
Feat.
J. Lancet
27:26
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
Feat.
J. Lancet
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
28:02
University of Colorado Division of Hematology
2024 Updates in AML
Feat.
C. McMahon
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Treatment Options for AML in 2024
Feat.
A. Perl
21:51
MyCancerHaven
Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…
Feat.
R. Vij,
G. Murthy
19:01
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 7+3 Is No Longer the Standard of Care
Feat.
T. Kadia
04:16
UChicago Medicine 12th International Clinical Cancer Genomics Conference
MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…
Feat.
L. Banaszak
14:58
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger P…
Feat.
C. McMahon
02:01
Emanuele Angelucci
Administration and Dosing of Tagraxofusp for BPDCN
48:04
Icahn School of Medicine at Mount Sinai
Integrating Targeted Therapies in AML
Feat.
H. Kantarjian
19:10
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center
Feat.
H. Kantarjian
27:28
UChicago Medicine
AML: Current Treatment Landscape and Key Recent Updates
Feat.
A. Patel
23:15
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
Feat.
M. Levis
